Alzamend Neuro annual stock-based compensation
2020
2021
2022
2023
2024
2025
2026
Alzamend Neuro Stock-Based Compensation Growth & History (ALZN)
Alzamend Neuro's stock-based compensation was $707,527 for fiscal 2026.
View full Alzamend Neuro company overviewAlzamend Neuro annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-30 | $707,527 | $382,419 | +117.63% |
| 2025 | 2025-04-30 | $325,108 | −$630,525 | −65.98% |
| 2024 | 2024-04-30 | $955,633 | −$2.6M | −73.33% |
| 2023 | 2023-04-30 | $3.6M | −$825,944 | −18.73% |
| 2022 | 2022-04-30 | $4.4M | $2.4M | +116.92% |
| 2021 | 2021-04-30 | $2.0M | $230,843 | +12.81% |
| 2020 | 2020-04-30 | $1.8M | — | — |
Alzamend Neuro quarterly stock-based compensation
Q1.21
Q2.21
Q2.21
Q3.21
Q1.22
Q2.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-04-30 | $623,811 | $542,534 | +667.51% |
| Q3 2026 | 2026-01-31 | $9,300 | −$71,977 | −88.56% |
| Q2 2026 | 2025-10-31 | $31,514 | −$49,763 | −61.23% |
| Q1 2026 | 2025-07-31 | $42,902 | −$38,375 | −47.22% |
| Q4 2025 | 2025-04-30 | $81,277 | $0 | 0.00% |
| Q3 2025 | 2025-01-31 | $81,277 | −$105,363 | −56.45% |
| Q2 2025 | 2024-10-31 | $81,277 | −$237,059 | −74.47% |
| Q1 2025 | 2024-07-31 | $81,277 | −$288,103 | −78.00% |
| Q4 2024 | 2024-04-30 | $81,277 | −$410,049 | −83.46% |
| Q3 2024 | 2024-01-31 | $186,640 | −$1.3M | −87.63% |
| Q2 2024 | 2023-10-31 | $318,336 | −$397,303 | −55.52% |
| Q1 2024 | 2023-07-31 | $369,380 | −$497,958 | −57.41% |
| Q4 2023 | 2023-04-30 | $491,326 | — | — |
| Q3 2023 | 2023-01-31 | $1.5M | $377,527 | +33.39% |
| Q2 2023 | 2022-10-31 | $715,639 | — | — |
| Q1 2023 | 2022-07-31 | $867,338 | $127,716 | +17.27% |
| Q3 2022 | 2022-01-31 | $1.1M | $555,668 | +96.62% |
| Q2 2022 · Oct 31 | 2021-10-31 | $1.3M | — | — |
| Q2 2022 · Oct 30 | 2021-10-30 | $1.3M | — | — |
| Q1 2022 | 2021-07-31 | $739,622 | $233,611 | +46.17% |
| Q3 2021 | 2021-01-31 | $575,127 | — | — |
| Q2 2021 · Oct 31 | 2020-10-31 | $654,359 | — | — |
| Q2 2021 · Oct 30 | 2020-10-30 | $568,937 | — | — |
| Q1 2021 | 2020-07-31 | $506,011 | — | — |
Alzamend Neuro stock-based compensation trends
Over the last five fiscal years, Alzamend Neuro's stock-based compensation decreased from $2.0M to $707,527, a change of −$1.3M. The latest reported quarter, Q4 2026, shows $623,811.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alzamend Neuro source filings ↗